A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Open to people ages 18 years and up

for Dose-Expansion:

• ≥ 18 years of age
• ECOG score ≤ 1
• Multiple myeloma (as per IMWG)
  • ≥ 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody
  • Patients must be refractory to their last prior therapy
  • Cohorts A1/A2: Patients must have exhausted available therapeutic options that are expected to provide a meaningful clinical benefit, either through disease relapse, treatment refractory disease, intolerance, or refusal of the therapy
  • t(4;14) confirmed by standard of care FISH testing
• Measurable disease, including at least 1 of the following criteria:
  • Serum M protein ≥ 0.50 g/dL (by SPEP)
  • Serum IgA ≥ 0.50 g/dL (IgA myeloma patients)
  • Urine M protein ≥ 200 mg/24 h (by UPEP)
  • sFLC involved light chain ≥ 10 mg/dL (100 mg/L) (patients with abnormal sFLC ratio)
  • Bone marrow plasma cells ≥ 30% (if only criterion for measurability)
• Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)

for Dose-Expansion:

• Treatment with the following therapies in the specified time period prior to first dose:
  • Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2
  • Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D
  • Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks
  • Cellular therapies ≤ 8 weeks
  • Autologous transplant < 100 days
  • Allogenic transplant ≤ 6 months, or > 6 months with active GVHD
  • Major surgery ≤ 4 weeks
• Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis

• MM with extramedullary disease (applies to Cohorts A1 & A2: KTX-1001, C1 & C2:

  Carfilzomib, and D: Pomalidomide only)

• Active CNS disease
• Inadequate bone marrow function
• Inadequate renal, hepatic, pulmonary, and cardiac function
• Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.
• Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 14 days or 5 half-lives prior to first dose
• Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)
• Active malignancy not related to myeloma requiring therapy within < 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.